2m 2m 2m 2m 2m 2m 2m
- $155.8MMarket Cap
- N/A1-Year Change
- BiotechnologyIndustry
Canton Strategic (CNTN)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Canton Strategic Holdings, Inc. Expected to Be Included in Russell 3000® and Russell 2000®
Canton Strategic Holdings, Inc. (NASDAQ: CNTN) announced it is expected to be included in the Russell 3000® Index and Russell 2000® Index following the semi-annual reconstitution effective June 26, 2026. The company is the first publicly traded firm to leverage Canton Coin to support the Canton Network's digitization of traditional financial markets.
06/18/2026, 8:15 AM • Benzinga
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025
Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.
09/03/2025, 7:30 AM • The Motley Fool
U.S. stock futures were slightly lower as the Jackson Hole Economic Symposium begins, with focus on Federal Reserve Chair Jerome Powell's upcoming speech and key corporate earnings reports from Walmart, Intuit, and Ross Stores.
08/21/2025, 8:38 AM • Benzinga
Peers
Statistics
MoreInformation as of 08/14/2026
Company Profile
Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States. It operates in two segments, Digital Asset Treasury and Clinical Stage Bio-technology. The company is involved in the operation of Canton Coin-centric digital asset treasury strategies, including validator operations and network participation; application support and strategic investments; collaboration and ecosystem advancement; capital raising and treasury expansion; token management - locking, lending, and options; Canton Foundation; and governance and risk management. It also researches and develops GV104, a buccal film formulation of nalmefene for the treatment of respiratory depression and prophylactic protection against synthetic opioid exposure in military and first responders; and GV023, an oral anti-tumor necrosis factor-alpha monoclonal antibody that addresses critical limitation of IV gold standard for the treatment of repeated intravenous infusions. The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026. Canton Strategic Holdings, Inc. was incorporated in 2017 and is headquartered in Red Bank, New Jersey.
Key Executives
- Mark Toomey
- Jacob Asbury
- Mark Wendland
- Angela Dominy Radkowski
Current Ownership Distribution
- Other56.2M (72.90%)
- Institutions12.2M (15.88%)
- Mutual Funds8.5M (11.01%)
- Insiders169,526 (0.22%)